Cutaneous aspergillosis has been described as primary or secondary to haematogenous dissemination (1). Primary cutaneous aspergillosis usually follows local trauma and appears as a purplish oedematous lesion at the site of inoculation (2). We present here a rare case of primary cutaneous aspergillosis, which manifested as intractable nodules.

CASE REPORT
A 66-year-old Japanese woman was referred to our clinic for evaluation of an asymptomatic nodule on the tip of her right thumb, which had appeared 1 month previously. Physical examination revealed a purplish nodule, 16 × 11 mm in size, with necrosis at the centre (Fig. 1). Her medical history was unremarkable. Results of routine laboratory examinations were within normal limits. The patient had engaged in flower gardening as a hobby for the past 3 years, but had experienced no trauma. She had worn gloves on her hands whenever she had touched vegetables and flowers. The lesion was clinically suspected to be a granuloma teleangiectaticum.

Histopathologically, there was massive epidermal necrosis and dermal necrobiosis. The periphery of the lesion showed dermal infiltration of lymphocytes. Numerous fungal elements were easily identified in the area of epidermal necrosis (not shown).

Grocott staining revealed septate hyphae with branches at the superficial necrotic areas and rarely in the dermal necrobiosis (Fig. 2). Aspergillus flavus was isolated by fungal culture from the biopsied specimen 2 weeks later. Based on these findings, a diagnosis of primary cutaneous aspergillosis, caused by A. flavus, was made.

The patient was treated with daily topical ketoconazole for 1 month, but this had no effect on the lesion. She was then treated with oral itraconazole, 100 mg daily for 1 month. However, the response was poor and the dosage of itraconazole was increased to 200 mg daily. This treatment resulted in complete healing of the lesion 13 weeks after the initiation of treatment.

DISCUSSION
Primary cutaneous aspergillosis is comparatively rare (3, 4). It usually develops in relation to local trauma (intravenous injection site, injury or burns) (2). Clinically, it is characterized by the presence of violaceous macules, papules, haemorrhagic bullae, ulcerations with central necrosis, and pustules or subcutaneous abscess (5). The occurrence of varying clinical manifestations of fungal diseases has been demonstrated in patients with altered host defences (4). Immunocompromised patients with primary cutaneous aspergillosis occasionally present with solitary non-ulcerated nodules (6, 7). Our case showed a purplish skin nodule with no deficiency of immunological function or any severe diseases associated with fungal infection. To our knowledge, such a case has been reported only once so far (3). The patient developed oedematous, nodular lesions on her face, ears and scalp, and A. niger was isolated from the skin lesions (3).
Fungi of the genus *Aspergillus* are widely distributed in the environment, particularly in soil and decomposed vegetation. The most frequent organisms causing cutaneous aspergillosis are *A. flavus* and *A. fumigatus*. Primary cutaneous aspergillosis, manifesting as a nodule on the finger, is predominantly caused by *A. flavus*, as in the present case. Although the patient reported that she had had no preceding trauma, we speculate that *A. flavus* was probably inoculated with a piece of wood or soil.

We believe the lesion to be primary aspergillosis because the fungal elements were found not only in the epidermal necrosis but also in the dermal necrobiosis. This is supported by the successful systemic antifungal therapy.

Recommended treatment for primary cutaneous aspergillosis includes voriconazole, itraconazole and amphotericin B. First-line therapy for such patients was previously intravenous amphotericin B (2). However, recent studies have suggested that a significant portion of *Aspergillus* species could be resistant to conventional treatment (8). Voriconazole has been shown to be statistically superior to amphotericin B as a treatment for aspergillosis in adults (9). Barret et al. (10) reported the usefulness of topical nystatin combined with systemic itraconazole. In the present case, oral administration of itraconazole (200 mg/day) was effective. It is therefore important for clinicians to consider the possibility of primary cutaneous aspergillosis, even if the patient is not immunocompromised.

REFERENCES